Logo

BNGO

Bionano Genomics, Inc.

BNGO

Bionano Genomics, Inc. • NASDAQ
$1.85 ▲ 2.21% (+0.04)
Market Cap $6.07 M
52w High $22.80
52w Low $1.45
Dividend Yield 0%
P/E -0.14
Volume 202.45K
Outstanding Shares 3.28M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $7.367M ▲ $12.063M ▲ $-8.503M ▼ -115.42% ▼ $-1.59 ▲ $-6.062M ▼
Q2-2025 $6.733M ▲ $11.277M ▼ $-6.857M ▼ -101.842% ▼ $-1.99 ▼ $-4.343M ▼
Q1-2025 $6.457M ▼ $11.403M ▼ $-3.102M ▲ -48.041% ▲ $-1.15 ▲ $-525K ▲
Q4-2024 $8.163M ▲ $15.358M ▼ $-20.125M ▲ -246.539% ▲ $-10.79 ▲ $-17.648M ▲
Q3-2024 $6.073M $35.455M $-44.246M -728.569% $-30.92 $-38.474M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $3.065M ▼ $79.062M ▲ $29.263M ▼ $49.799M ▲
Q2-2025 $16.438M ▼ $76.01M ▼ $30.636M ▲ $45.374M ▼
Q1-2025 $18.231M ▲ $78.414M ▲ $30.226M ▼ $48.188M ▲
Q4-2024 $9.475M ▼ $76.67M ▼ $41.295M ▲ $35.375M ▼
Q3-2024 $22.954M $87.362M $38.494M $48.868M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-8.503M ▼ $-5.919M ▼ $-4.669M ▼ $10.076M ▲ $-497K ▼ $-5.919M ▼
Q2-2025 $-6.856M ▼ $-3.487M ▼ $1.979M ▲ $1.469M ▼ $-63K ▲ $-3.487M ▼
Q1-2025 $-3.102M ▲ $-2.764M ▲ $-14.066M ▼ $10.891M ▲ $-5.948M ▼ $-2.764M ▲
Q4-2024 $-20.125M ▲ $-6.504M ▲ $2.997M ▲ $3.89M ▼ $379K ▲ $-6.504M ▲
Q3-2024 $-44.246M $-13.309M $-5.375M $6.021M $-12.639M $-13.309M

Revenue by Products

Product Q2-2024Q3-2024Q4-2024Q2-2025
Consumable Revenue
Consumable Revenue
 $0 ▲$0 ▲$10.00M ▲$0 ▼
Instrument Revenue
Instrument Revenue
 $0 ▲$0 ▲$10.00M ▲$0 ▼
Product
Product
 $10.00M ▲$10.00M ▲$10.00M ▲$10.00M ▲
Product and Service Other
Product and Service Other
 $0 ▲$0 ▲$0 ▲$0 ▲
Software
Software
 $0 ▲$0 ▲$0 ▲$0 ▲

Five-Year Company Overview

Income Statement

Income Statement Revenue remains very small and has grown only modestly over the past few years, while operating expenses have stayed high. The company has reported steady and sizable losses every year, with no sign yet of moving toward break‑even. Earnings per share look extremely negative, largely because of repeated reverse stock splits that mechanically inflate the per‑share loss, but the underlying message is simple: the business is still in an early, heavy‑investment phase with revenue far from covering its cost base.

Balance Sheet

Balance Sheet The balance sheet has weakened over time. Total assets and shareholders’ equity have both come down from earlier peaks, suggesting sustained losses and limited fresh capital. Cash on hand is relatively low compared with the pace of historical cash burn, and there is a meaningful layer of debt for a company this small. Overall, financial flexibility appears constrained, and the business likely depends on continued access to capital markets or partners to support operations.

Cash Flow

Cash Flow The company consistently uses cash rather than generating it. Operating cash flow has been negative for many years, and free cash flow closely tracks that pattern because investment in physical assets is minimal. In plain terms, most cash goes to funding ongoing R&D, sales, and overhead, with little offset from incoming cash from customers. This creates ongoing funding pressure: without a shift in revenue or cost structure, Bionano must continue to rely on external financing to sustain its strategy.

Competitive Edge

Competitive Edge Bionano occupies a specialized niche in genomics with its Optical Genome Mapping technology, which focuses on large structural changes in DNA that traditional sequencing can miss or struggle with. This gives it a differentiated role: instead of directly competing head‑to‑head with big sequencing players, it often complements them by filling a gap in structural variation detection. The company has built a meaningful base of installed systems, proprietary consumables, and software, supported by patents and scientific publications. However, Bionano is still a small player in a market dominated by large, well‑funded companies, and its success depends on persuading labs and clinics to add a new technology to established workflows and budgets.

Innovation and R&D

Innovation and R&D Innovation is the core of Bionano’s story. Its Saphyr and newer Stratys instruments, paired with the VIA software platform and specialized sample prep kits, form an integrated solution for structural variant analysis. The company is also expanding into clinical testing services, leveraging OGM‑based assays and a certified lab to showcase real‑world use cases. Future efforts focus on more automated, higher‑throughput instruments, smarter software (including AI‑driven analysis), a broader menu of clinical tests, and global expansion. This R&D‑heavy path offers meaningful upside if adoption accelerates, but it is costly and time‑sensitive: the company must convert technical advances into recurring, paying users quickly enough to justify ongoing investment.

Summary

Bionano Genomics combines a compelling technology story with a fragile financial profile. On the positive side, it has a clearly differentiated platform in Optical Genome Mapping, an ecosystem of instruments, consumables, software, and services, and a strategy that complements rather than directly replaces existing sequencing tools. The market need for better structural variation detection in cancer and genetic disease is real, and Bionano’s IP, publications, and early clinical traction support the scientific case. On the risk side, the business is still small, unprofitable, and cash‑consuming, with a thinner balance sheet than in prior years and visible reliance on external funding. Reverse stock splits and shrinking equity highlight shareholder dilution and ongoing financial pressure. Future outcomes hinge on a few key uncertainties: how quickly labs and clinics adopt OGM, whether reimbursement and regulatory milestones translate into routine clinical use, and whether the company can manage its cash burn while continuing to innovate. Overall, Bionano represents a high‑innovation, high‑execution‑risk profile where technology leadership must still be converted into durable commercial and financial strength.

NEWS

November 13, 2025 · 4:01 PM UTC

Bionano Reports Third Quarter 2025 Results and Highlights Recent Business Progress

Read more

November 6, 2025 · 8:00 AM UTC

Bionano Announces Publication Showing OGM Can Overcome Key Limitations of Targeted RNA-Seq for Cytogenetic Investigation in Acute Leukemia

Read more

October 30, 2025 · 4:05 PM UTC

Bionano to Report Third Quarter 2025 Financial Results and Host a Conference Call Webcast on November 13, 2025

Read more

October 7, 2025 · 8:00 AM UTC

Bionano to Participate in the H.C. Wainwright @ Home Event

Read more

September 17, 2025 · 5:00 PM UTC

Bionano Genomics, Inc. Announces Closing of $10 Million Public Offering

Read more